SCA
AEGR

Secor Capital Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Secor Capital Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-19,469
Closed -$369K – 688
2015
Q2 		$369K Buy
+19,469
New +$421K 0.13% 264

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Secor Capital Advisors's AEGR Position: Q3 2015 in Review

Secor Capital Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2015, closing a stake of 19,469 shares — an estimated $369K sold.

Secor Capital Advisors first reported a position in AEGR in Q2 2015 and held it in 1 quarter. The position peaked at $369K in Q2 2015. 96 funds tracked by Wall St. Rank hold AEGR as of Q3 2015.

  • Secor Capital Advisors reported no remaining Aegerion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Secor Capital Advisors sold 19,469 Aegerion Pharmaceuticals shares in Q3 2015, an estimated $369K.
  • Secor Capital Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Secor Capital Advisors's Aegerion Pharmaceuticals position peaked at $369K in Q2 2015.
  • 96 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2015.

Based on Secor Capital Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.